全文获取类型
收费全文 | 14489篇 |
免费 | 879篇 |
国内免费 | 545篇 |
专业分类
耳鼻咽喉 | 26篇 |
儿科学 | 280篇 |
妇产科学 | 104篇 |
基础医学 | 1676篇 |
口腔科学 | 131篇 |
临床医学 | 1334篇 |
内科学 | 3146篇 |
皮肤病学 | 139篇 |
神经病学 | 732篇 |
特种医学 | 233篇 |
外科学 | 882篇 |
综合类 | 2176篇 |
现状与发展 | 1篇 |
预防医学 | 644篇 |
眼科学 | 85篇 |
药学 | 3335篇 |
5篇 | |
中国医学 | 686篇 |
肿瘤学 | 298篇 |
出版年
2023年 | 98篇 |
2022年 | 183篇 |
2021年 | 372篇 |
2020年 | 370篇 |
2019年 | 263篇 |
2018年 | 325篇 |
2017年 | 310篇 |
2016年 | 383篇 |
2015年 | 355篇 |
2014年 | 684篇 |
2013年 | 1177篇 |
2012年 | 710篇 |
2011年 | 800篇 |
2010年 | 665篇 |
2009年 | 589篇 |
2008年 | 694篇 |
2007年 | 685篇 |
2006年 | 631篇 |
2005年 | 601篇 |
2004年 | 562篇 |
2003年 | 550篇 |
2002年 | 460篇 |
2001年 | 422篇 |
2000年 | 391篇 |
1999年 | 345篇 |
1998年 | 292篇 |
1997年 | 314篇 |
1996年 | 276篇 |
1995年 | 232篇 |
1994年 | 215篇 |
1993年 | 187篇 |
1992年 | 187篇 |
1991年 | 157篇 |
1990年 | 148篇 |
1989年 | 133篇 |
1988年 | 126篇 |
1987年 | 110篇 |
1986年 | 111篇 |
1985年 | 135篇 |
1984年 | 150篇 |
1983年 | 83篇 |
1982年 | 91篇 |
1981年 | 85篇 |
1980年 | 71篇 |
1979年 | 34篇 |
1978年 | 34篇 |
1977年 | 27篇 |
1976年 | 22篇 |
1975年 | 16篇 |
1974年 | 22篇 |
排序方式: 共有10000条查询结果,搜索用时 296 毫秒
991.
992.
Ubogu EE Hong ST Akman HO Dimauro S Katirji B Preston DC Shapiro BE 《Muscle & nerve》2005,32(5):675-681
A 62-year-old man developed progressive gait instability, bladder dysfunction, proximal weakness, distal sensory loss, and mild cognitive impairment over 6 years. Neurologic examination revealed upper and lower motor neuron dysfunction in the lower extremities, with distal sensory loss. Electrodiagnostic studies, magnetic resonance imaging of the brain, and sural nerve biopsy were consistent with adult polyglucosan body disease. Biochemical and genetic analyses demonstrated reduced glycogen brancher enzyme levels associated with a heterozygous point mutation (Tyr329Ser or Y329S) in the glycogen brancher enzyme gene on chromosome 3. Mutational heterozygosity in the glycogen brancher enzyme gene has not been previously reported as a cause for this rare disease. A review of the clinical presentation, pathogenesis, etiology, and diagnosis of this disease is presented. 相似文献
993.
Naseem RH Hedegard W Henry TD Lessard J Sutter K Katz SA 《Basic research in cardiology》2005,100(2):139-146
Plasma renin activity (PRA) is often found to increase after
myocardial infarction (MI). Elevated PRA may contribute to increased
myocardial angiotensin II that is responsible for maladaptive remodeling of
the myocardium after MI. We hypothesized that MI would also result in cardiac
release of cathepsin D, a ubiquitous lysosomal enzyme with high renin
sequence homology. Cathepsin D release from damaged myocardial tissue
could contribute to angiotensin formation by acting as an enzymatic alternate
to renin. We assessed circulating renin and cathepsin D from both control and
MI patient plasma (7–20 hours after MI) using shallow gradient focusing that
allowed for independent measurement of both enzymes. Cathepsin D was
increased significantly in the plasma after MI (P < 0.001). Furthermore, circulating
active cathepsin D metabolites were also signi.cantly elevated after
MI (P < 0.04), and contained the majority of cathepsin D activity in plasma.
Spiking control plasma with cathepsin D resulted in a variable but significant
(P = 0.005) increase in PRA using a clinical assay. We conclude that 7–20
hours after MI, plasma cathepsin D is significantly elevated and most of the
active enzymatic activity is circulating as plasma metabolites. Circulating
cathepsin D can falsely increase clinical PRA determinations, and may also
provide an alternative angiotensin formation pathway after MI. 相似文献
994.
Letson GW Shapiro CN Kuehn D Gardea C Welty TK Krause DS Lambert SB Margolis HS 《The Journal of pediatrics》2004,144(3):327-332
OBJECTIVE: To determine the effect of maternal antibody on hepatitis A vaccine immunogenicity in infants.Study design Infants of mothers negative for antibody to hepatitis A virus (anti-HAV; group 1) were administered hepatitis A vaccine at 2, 4, and 6 months of age, and infants of anti-HAV-positive mothers were randomized to receive either hepatitis A vaccine (group 2) or hepatitis B vaccine (group 3) on the same schedule. Group 3 infants subsequently received hepatitis A vaccine at 8 and 10 months of age. RESULTS: At 15 months of age, 100% of infants in group 1, 93% in group 2, and 92% in group 3 had protective levels of antibody. However, there were significant differences in the geometric mean concentration (GMC) of anti-HAV between groups. Group 1 GMC was 231 mIU/mL, compared with 85 mIU/mL for group 2 and 84 mIU/mL for group 3 (P<.001, group 1 vs group 3). CONCLUSIONS: Passively acquired maternal anti-HAV resulted in a significantly lower final antibody response when infants were administered hepatitis A vaccine at 2, 4, and 6 months of age or at 8 and 10 months of age. 相似文献
995.
Essential hypertension is a major cause of cardiovascular morbidity and mortality in the Western world, yet it remains poorly controlled. Single drug-antihypertensive therapy is unsuccessful in up to half of all patients with hypertension; although lack of adherence may account for a proportion of this, there is evidence of considerable variation in the response of different hypertensive patients to different drug classes. A number of algorithms have been proposed in the literature, with a view to predicting an individual's response to different antihypertensive agents. However, even using such algorithms, hypertension control remains problematic, and they are frequently difficult to apply in everyday clinical practice. Initiation of treatment with low-dose combination antihypertensive therapy, using a drug which reduces total body sodium and/or volume in combination with a drug which blocks the renin-angiotensin system, provides an effective and easily applicable means to improve hypertension control in the primary care setting. 相似文献
996.
BACKGROUND: Blockade of the angiotensin II type 1 (AT1) receptor has been demonstrated to ameliorate splanchnic hypoperfusion in acute experimental circulatory failure. This study focused on hemodynamic changes and survival in pigs treated with AT1 blockade prior to or during acute endotoxinemia. METHODS: Escherichia coli lipopolysaccharide endotoxin was infused in anesthetized and mechanically ventilated pigs. Systemic, renal, mesenteric and jejunal mucosal perfusion as well as systemic oxygen and acid-base balance were monitored. The selective AT1 receptor blocker candesartan was administered prior to as well as during endotoxinemia. Control animals received the saline vehicle. RESULTS: Pre-treatment with candesartan resulted in higher survival rate (83%, 10 out of 12 animals) compared with 50% (6 of 12) in control animals and 27% (3 of 11) in animals treated during endotoxinemia. Pre-treatment with candesartan resulted in higher cardiac output, mixed venous oxygen saturation, arterial standard base-excess, portal venous blood flow during endotoxin infusion compared with controls and animals treated during endotoxinemia. No adverse effects were found on neither systemic nor renal circulation. CONCLUSION: The favorable results of AT1 receptor blockade prior to endotoxinemia are lost when blockade is established during endotoxinemia demonstrating the importance of the renin-angiotensin system and its dynamic involvement in acute endotoxinemic shock. 相似文献
997.
Association between captopril, other antihypertensive drugs and risk of prostate cancer 总被引:3,自引:0,他引:3
Ronquist G Rodríguez LA Ruigómez A Johansson S Wallander MA Frithz G Svärdsudd K 《The Prostate》2004,58(1):50-56
BACKGROUND: There has been some debate on the existence of an association between hypertension, antihypertensive medications and cancer risk. METHODS: We performed a nested case-control study to assess the association between the risk of prostate cancer and the use of the angiotensin converting enzyme (ACE)-inhibitor captopril, and other antihypertensive drugs. We used data from the General Practice Research Database in UK. RESULTS: We found an incidence rate of prostate cancer of 1.61 per 1,000 person-years among male patients aged 50-79 years old. Patients with a history of benign prostatic hyperplasia and/or prostatism carried a two-fold greater risk of prostate cancer than those without such antecedents. None of the other studied co-morbidities were associated with prostate cancer. We found that users of captopril had a relative risk of 0.7 (95% CI: 0.4-1.2) to develope prostate cancer. None of the other studied individual ACE-inhibitors shared a similar effect with the one observed for captopril. CONCLUSIONS: No clear association was apparent between the use of antihypertensive drugs and prostate cancer. However, specific focus on users of captopril showed a lower risk of subsequent prostate cancer. Further research is needed to explore this association. 相似文献
998.
BACKGROUND: Angiotensin II (Ang II) is a potent vasoconstrictor that modulates microvascular permeability. Angiotensin II type 1 (AT1) and type 2 (AT2) receptors have been described with subsequent development of their respective antagonists. We hypothesized that the AT2 receptor modulates microvascular permeability. MATERIALS AND METHODS: Hydraulic permeability (L(p)) was measured in rat mesenteric venules using the Landis micro-occlusion technique. Following baseline L(p) measurements, paired measures of microvessel L(p) were obtained after perfusion with a test solution. The test solutions consisted of the AT2 receptor agonist CGP42112A at 10 microm (n = 6), 100 microm (n = 6), and 200 microm (n = 6), as well as the AT2 receptor antagonist PD-123319 at 3 microm (n = 6), 30 microm (n = 6), 300 microm (n = 6), and 600 microm (n = 6). RESULTS: From mean baseline L(p) of 0.99 +/- 0.03, 100 microm CGP42112A decreased L(p) to 0.76 +/- 0.02 (P = 0.005), and 200 microm CGP42112A decreased L(p) to 0.61 +/- 0.02 (P < 0.001). From mean baseline L(p) of 0.90 +/- 0.05, PD-123319 increased L(p) at 30 microm to 1.60 +/- 0.2 (P = 0.003), at 300 microm to 2.28 +/- 0.3 (P = 0.008), and at 600 microm to 4.30 +/- 0.9 (P = 0.03). Units for L(p) are mean +/- SEM x 10(-7) cm s(-1) cmH(2)O(-1). CONCLUSION: AT2 activation decreased L(p), while AT2 blockade increased L(p). These changes in L(p) may be explained by (1). a permeability-decreasing effect of the AT2 receptor that is induced by AT2 activation and inhibited by AT2 blockade; and/or (2). a permeability-increasing effect of the AT1 receptor observed during AT2 blockade and selective AT1 activation by endogenous locally released Ang II. These mechanisms would support the theories that the AT1 receptor increases microvascular permeability, while the AT2 receptor decreases microvascular permeability. 相似文献
999.
Two different therapeutic regimes in patients with sequelae of hemolytic-uremic syndrome 总被引:3,自引:0,他引:3
Caletti MG Lejarraga H Kelmansky D Missoni M 《Pediatric nephrology (Berlin, Germany)》2004,19(10):1148-1152
Renal disease is the most important long-term complication of hemolytic-uremic syndrome (HUS). A comparative study of renal function was carried out in two groups of patients. Group 1 included 19 children followed for a median of 11 years, 1960–1980, with a low-sodium diet, antihypertensive drugs, and a restricted protein intake in the end stage of renal disease. Group 2 included 26 children treated for a median of 9 years, 1988–2002, on a low-sodium diet, early restriction of protein intake according to recommendations, and angiotensin converting enzyme inhibitors (ACEi). Long-term renal function was assessed by the inverse of the plasma creatinine concentration (1/[Cr]) over time. Linear regression lines were fitted to individual values of 1/[Cr] for each child. Regression coefficients of children in group 1 were all negative, ranging from –0.031 to –0.00043; 7 were significantly different from zero, indicating a linear fall in renal function over time. In contrast, children from group 2 had 11 negative slopes (only 1 significant) and 15 positive slopes, ranging from 0.17893 to –0.3899. Fishers exact test showed that group 1 had significantly more children with negative slopes than group 2. This comparatively better long-term outcome of renal function in children under contemporary treatment was probably associated with early restriction of protein and use of ACEi. 相似文献
1000.
Enalapril dosage in steroid-resistant nephrotic syndrome 总被引:9,自引:5,他引:4
We have examined, in a randomized crossover trial, the antiproteinuric effect of treatment with low- (0.2 mg/kg daily) and high-dose (0.6 mg/kg daily) enalapril in 25 consecutive patients with steroid-resistant nephrotic syndrome (SRNS). Patients in group A (n=11) received enalapril at low doses for 8 weeks, followed by 2 weeks of washout and then at high doses for 8 weeks. Those in group B (n=14) initially received enalapril at high and then low doses. Patients continued to receive treatment with tapering doses of prednisolone; none received concomitant therapy with daily oral or intravenous steroids, alkylating agents, cyclosporine, non-steroidal anti-inflammatory drugs, and other antihypertensive medications. The urine albumin-to-creatinine (Ua/Uc) ratio and the percentage reduction were determined for each phase of therapy. Baseline clinical, biochemical, and histological features were comparable in the two groups. In the first phase, treatment with low-dose enalapril (group A) resulted in median 34.8% Ua/Uc reduction compared with 62.9% with high doses (group B) (P<0.01). High-dose enalapril was associated with a significant reduction in Ua/Uc ratio in both groups. The combined median Ua/Uc (95% confidence interval) reduction in the low-dose phase was 33% (–10.3% to 72.4%) and in the high-dose 52% (15.4%–70.4%) (P<0.05). The median Ua/Uc ratio at the end of 20 weeks was 1.1 and 1.8 in groups A and B, respectively (P>0.05). Systolic and diastolic blood pressure reductions were similar in both groups. No period or carry-over effect was found. Prolonged treatment with enalapril thus resulted in a dose-related reduction in nephrotic-range proteinuria. Titration of the dose of enalapril may be a useful strategy for achieving substantial reduction of proteinuria in children with SRNS. 相似文献